(株)ペルセウスプロテオミクス
株価チャート
2026/08/21 更新株価トレンド
2026/08/21 更新株価・取引詳細
2026/08/21 更新株価
取引
株主構成
2026/08/01 更新財務パフォーマンス
2026/08/23 更新売上・利益
利益率
キャッシュフロー
財務健全性
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| 損益計算書 | ||||
| 売上高 | ¥1億 | ¥1億 | ¥1億 | ¥1億 |
| 売上総利益 | ¥1億 | ¥1億 | ¥1億 | ¥1億 |
| 営業利益 | -¥7億 | -¥9億 | -¥8億 | -¥7億 |
| 経常利益 | -¥7億 | -¥9億 | -¥8億 | -¥7億 |
| 当期純利益 | -¥8億 | -¥11億 | -¥9億 | -¥7億 |
| EPS | -¥66.93 | -¥93.69 | -¥63.41 | -¥48.17 |
| 営業利益率 | -740.72% | -891.15% | -686.55% | -549.75% |
| 貸借対照表 | ||||
| 総資産 | ¥26億 | ¥17億 | ¥18億 | ¥16億 |
| 純資産 | ¥24億 | ¥14億 | ¥14億 | ¥12億 |
| 総負債 | ¥2億 | ¥3億 | ¥4億 | ¥4億 |
| 現金 | ¥24億 | ¥15億 | ¥17億 | ¥15億 |
| 有利子負債 | - | - | - | - |
| 自己資本比率 | 93.37% | 82.56% | 78.75% | 75.01% |
| D/Eレシオ | 0.00 | 0.00 | 0.00 | 0.00 |
| キャッシュフロー | ||||
| 営業CF | -¥6億 | -¥8億 | -¥7億 | -¥7億 |
| 投資CF | -¥2億 | -¥2億 | -¥1億 | -¥0億 |
| 財務CF | -¥0億 | ¥1億 | ¥9億 | ¥5億 |
| フリーCF | -¥7億 | -¥10億 | -¥8億 | -¥7億 |
| 効率性 | ||||
| ROE | -32.84% | -78.98% | -63.17% | -58.97% |
| ROA | -30.66% | -65.21% | -49.75% | -44.23% |
最新IR情報
最新ニュース (5件)
企業情報
会社概要
Perseus Proteomics Inc., a drug discovery biotech venture company, develops and sells antibody-based pharmaceuticals and research reagents for cancer and other diseases in Japan. The company is involved in the antibody discovery activities; and antibody research support activities comprising hybridoma antibody sequencing, antibody protein production, and contract antibody research activities, as well as supply of antibody products. Its product pipeline includes PPMX-T001, an anti-hepatocarcinoma antibody; PPMX-T002, an anticancer drug; PPMX-T003, a drug for the treatment of adult T-cell; and PPMX-T004, an antibody drug conjugate. Perseus Proteomics Inc. has a joint research agreement with ASKA Pharmaceutical Co., Ltd. for the development of new antibody drugs and therapeutic drugs for specific disease areas. Perseus Proteomics Inc. was incorporated in 2001 and is headquartered in Tokyo, Japan.
